Overview
Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Moscow. It corresponds to a fragment of the natural ACTH(4-10) sequence with the addition of a proline-glycine-proline tail that confers metabolic stability.
Although derived from ACTH, Semax does not exhibit corticotropic activity at therapeutic doses. The structural modifications eliminated HPA-axis engagement while preserving the neuromodulatory activity attributed to the ACTH(4-10) core.
Semax has been studied in Russia for several decades in the contexts of acute ischemic stroke, mild cognitive impairment, and ADHD-spectrum conditions. It is registered as a medical drug in Russia but is not approved by FDA, EMA, or comparable Western regulators.
Mechanism of Action
The dominant mechanistic finding is up-regulation of brain-derived neurotrophic factor (BDNF) in hippocampal tissue, with parallel effects on the high-affinity receptor TrkB. This pathway is widely implicated in neuroplasticity and recovery from ischemic injury.
Semax also modulates several monoaminergic systems — particularly serotonergic and dopaminergic — and influences the expression of immediate-early genes (c-fos, c-jun) in cortical and limbic regions.
Intranasal administration produces detectable behavioural and electrophysiological effects within minutes, suggesting either rapid CNS penetration via the olfactory route or peripheral signalling that secondarily reaches the brain.
Research Summary
- Brain protein-expression profiling confirmed a protective effect of Semax in a rat model of cerebral ischemia-reperfusion. [1]
- Antidepressant-like and antistress effects were reported for Semax in a chronic-unpredictable-stress rat model. [2]
- Correction of CNS deficits following antenatal and postnatal hypoxia has been reported with peptide-hormone treatment including ACTH(4-10) analogs. [3]
What we don't know yet
- Pharmacokinetic profile after intranasal administration in humans is poorly published in the English-language literature.
- Direct comparison with established nootropic compounds is scarce.
- Long-term cognitive and structural-brain safety data are limited.
Protocol Considerations
Research framing only. The Protides Research Library does not provide dosing guidance for human use. The figures below summarise published research-protocol ranges and storage conditions; they are not clinical recommendations.
Stack Interactions
Storage & Handling
- Lyophilised
- −20 °C, desiccated, dark.
- Reconstituted
- 2–8 °C in sterile water or saline. Intranasal solutions should be discarded after 30 days.
- Shelf life
- Lyophilised ≥ 24 months at −20 °C. Reconstituted ~30 d at 2–8 °C.
FAQ
Is Semax related to ACTH?
Yes — it is a modified ACTH(4-10) fragment with a stabilising C-terminal tail. It does not retain corticotropic activity.
How is it typically administered in research?
Most published research uses intranasal administration of a saline solution.
Is it approved as a drug?
Registered in Russia for stroke and cognitive indications; not approved by FDA, EMA, or comparable regulators.
Does it cross the blood-brain barrier?
Functional CNS effects are well documented; direct measurement of intact passage is more limited.
What is the difference between Semax and Selank?
Different sequences, different parent peptides. Semax derives from ACTH; Selank from the immune-modulating peptide tuftsin.
What is the most replicated finding?
Neuroprotection in rodent MCAO models, supported by BDNF up-regulation data.
References
- [1]
- [2]
- [3]The effects of ante- and postnatal hypoxia on the central nervous system and their correction with peptide hormonesNeurosci. Behav. Physiol., 2003
